Status:
COMPLETED
Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)
Lead Sponsor:
Aradigm Corporation
Collaborating Sponsors:
Grifols Therapeutics LLC
Conditions:
Non Cystic Fibrosis Bronchiectasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study (ARD-3150-1201, ORBIT-3) will evaluate the safety and efficacy of inhaled Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects who have a confirmed di...
Eligibility Criteria
Inclusion
- Verified bronchiectasis diagnosis
- Pseudomonas aeruginosa lung infection
Exclusion
- Cystic Fibrosis
Key Trial Info
Start Date :
March 31 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
278 Patients enrolled
Trial Details
Trial ID
NCT01515007
Start Date
March 31 2014
End Date
October 1 2016
Last Update
March 26 2021
Active Locations (109)
Enter a location and click search to find clinical trials sorted by distance.
1
Peoria, Arizona, United States
2
Phoenix, Arizona, United States
3
Downey, California, United States
4
Los Angeles, California, United States